We are excited to share the overall survival results from studies -010 and -003, as these data provide new insights into the long-term efficacy and safety of Opdivo in previously treated advanced renal cell carcinoma, said Vicki Goodman, M.D., Development Lead, Melanoma and Genitourinary Cancers,